Cytotoxic effect of Efavirenz in BxPC‑3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation
Open Access
- 5 December 2017
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (2) , 1728-1736
Abstract
The non-nucleoside reverse transcriptase inhibitor (NNRTI) Efavirenz is frequently used in human immunodeficiency virus treatment, but also efficient against cancer in mouse models. Its radiosensitizing effect makes it a promising drug for combination with radiotherapy. The efficacy of Efavirenz combined with irradiation was assessed with immunostaining of DNA‑damage markers and colony formation assays in BxPC‑3 pancreatic cancer cells. Gene expression and protein phosphorylation of the Efavirenz‑sensitive BxPC‑3 cells was compared to the resistant primary fibroblasts SBL‑5. Oxidative stress, mitochondrial damage and cell death were studied with live‑cell microscopy and flow cytometry. Combined Efavirenz and radiation significantly increased the number of γH2AX and phospho‑ataxia telangiectasia mutated foci. Efavirenz and ionizing radiation had a synergistic effect using the clonogenic survival assay. Efavirenz selectively induced cell death in the BxPC‑3 cells. The differing gene expression of cell cycle and apoptotic regulator genes in both cell cultures after Efavirenz treatment match with this selective effect against cancer cells. In the phosphoprotein array, an early phosphorylation of extracellular signal‑related kinase 1/2 and p38 mitogen‑activated protein kinase was notably detected in the cancer cells. The phosphorylation of AKT decreased in the cancer cells whereas it increased in the fibroblasts. Oxidative stress and mitochondrial membrane depolarization appeared in the cancer cells immediately after Efavirenz treatment, but not in the fibroblasts. Efavirenz has an anti‑cancer effect against pancreatic cancer mainly by the induction of oxidative stress. The antitumor potential of Efavirenz and radiotherapy are additive.Keywords
This publication has 43 references indexed in Scilit:
- The slow cell death response when screening chemotherapeutic agentsCancer Chemotherapy and Pharmacology, 2010
- Inhibition of Mitochondrial Function by Efavirenz Increases Lipid Content in Hepatic CellsHepatology, 2010
- Enhanced oxidative stress and increased mitochondrial mass during Efavirenz‐induced apoptosis in human hepatic cellsBritish Journal of Pharmacology, 2010
- Erratum: Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivoThe Prostate, 2009
- Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy aloneBlood, 2008
- Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1—Infected PersonsHIV Research & Clinical Practice, 2008
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Reinduction of Cell Differentiation and 131 I Uptake in a Poorly Differentiated Thyroid Tumor in Response to the Reverse Transcriptase (RT) Inhibitor NevirapineCancer Biotherapy and Radiopharmaceuticals, 2007
- Cell differentiation and iodine-131 uptake in poorly differentiated thyroid tumour in response to nevirapineThe Lancet Oncology, 2006
- HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy aloneEuropean Journal of Haematology, 2004